PHASE 1B TRIAL OF MONALIZUMAB (NKG2A INHIBITOR) PLUS DURVALUMAB: SAFETY AND EFFICACY IN PATIENTS WITH METASTATIC OVARIAN, CERVICAL, AND MICROSATELLITE-STABLE ENDOMETRIAL CANCERS-MedSci.cn

PHASE 1B TRIAL OF MONALIZUMAB (NKG2A INHIBITOR) PLUS DURVALUMAB: SAFETY AND EFFICACY IN PATIENTS WITH METASTATIC OVARIAN, CERVICAL, AND MICROSATELLITE-STABLE ENDOMETRIAL CANCERS

Banerjee, S; Oaknin, A; Sanchez-Simon, I; Salgado, AC; Patel, SP; Oza, A; Das, M; Kourtesis, P; Ascierto, ML; Diamond, JR

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020; 30 (): A86

科室
- - 订阅+
  - 更多科室
工具
服务